Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health serum fibrosis testing Coverage Updat…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Serum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and limitations for serum biomarker and multianalyte panel testing used to evaluate and monitor hepatic fibrosis in individuals with chronic liver disease; it affects providers submitting claims to Oscar Health for these tests.

    Policy Summary
    PayerOscar Health
    PolicySerum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease
    Policy CodePolicy N/A
    Change TypeMinor editorial — no material coverage changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionProviders must document medical necessity and may order ELF™ or FibroTest® once every six months for MASLD/MASH, alcoholic hepatitis, or to evaluate elevated liver stiffness for cACLD.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    every 6 monthsELF/FibroTest frequency allowed
    ELF™, FibroTest®, HBV/HCV FibroSURE®Not covered outside specified indications
    LIVERFASt™Explicitly not meeting criteria
    ~28 refs

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Guideline evidence summarized
    0.77FibroTest mean AUC (NAFLD)

    Coverage Criteria for Serum and Multianalyte Fibrosis Testing

    Permitted serum testing

    Covered when ALL of the following are met

    Allowed use of ELF™/FibroTest®: ELF™ (ELFTM) or FibroTest® testing once every six months is allowed for individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) including MASH, or alcoholic hepatitis, or to rule out compensated advanced chronic liver disease (cACLD) for individuals with an elevated liver stiffness measurement.frequency: <= once per 6 months

    Supportive documentation of diagnosis or elevated liver stiffness required

    Disallowed assays

    Not allowed tests (policy-level): Use of other multianalyte assays with algorithmic analysis (e.g., LIVERFASt™) does not meet criteria for any situation.

    Not medically necessary for other liver disease

    Not covered indications: For individuals with liver disease not meeting the specific indications above, the use of ELF™, FibroTest®, HBV FibroSURE®, and/or HCV FibroSURE® does not meet criteria.

    Guideline-concordant indications and thresholds

    Covered when used in accordance with guideline-recommended indications and thresholds

    AASLD/HCV guidance: Evaluate for advanced hepatic fibrosis in all persons with HCV using noninvasive tests (serum panels, elastography) or biopsy as needed to guide treatment and cirrhosis management.per guideline

    Recommendation I, A; use NITs to inform treatment and surveillance decisions

    AASLD NAFLD recommendations: Use NFS or FIB-4 to identify NAFLD patients at higher likelihood of bridging fibrosis or cirrhosis; use elastography or MRE to identify advanced fibrosis. ELF may be used as a prognostic biomarker when elastography is not available.FIB-4 >1.3 suggests further testing

    ELF approved as prognostic biomarker when elastography unavailable

    AGA NAFLD staging: Use NITs for risk stratification; FIB-4 <1.3 has strong negative predictive value to exclude advanced fibrosis; combine ≥2 NITs for staging if FIB-4 >1.3; consider biopsy for indeterminate or discordant results.

    Guideline-based coverage and use criteria

    Guideline-driven recommendations for use of non-invasive tests:

    WHO recommendations: APRI is recommended in resource-limited settings to assess for presence of cirrhosis (APRI >2 in adults). For significant fibrosis (≥F2) use APRI >0.5 or transient elastography >7.0 kPa; cirrhosis (F4) may be based on clinical criteria or APRI >1.0 or transient elastography >12.5 kPa.APRI >0.5; APRI >1.0; APRI >2; TE >7.0 kPa; TE >12.5 kPa

    WHO guidance referenced (2015, updated 2024).

    EASL / Joint societies: Biomarkers and transient elastography are acceptable non-invasive procedures to identify patients at low risk of advanced fibrosis/cirrhosis; combining biomarkers and TE may increase diagnostic accuracy. NITs are better for ruling out than confirming advanced fibrosis; patented tests (ELF, FibroTest) and TE are recommended in specialised settings, with LSM thresholds (≥10 and ≥15 kPa) supportive for cACLD assessment.LSM ≥10 kPa; LSM ≥15 kPa

    EASL guidance supports first-line use and describes limitations; follow-up intervals for NAFLD (e.g., reassess every 3 years) noted.

    Use of other multianalyte assays that rely on proprietary algorithms (for example, LIVERFASt™) is explicitly excluded and does not meet criteria for coverage in any situation described by this policy. This exclusion applies regardless of clinical indication or setting.

    FibroTest™ has demonstrated variable performance in NAFLD: a meta-analysis reported a mean AUC of 0.77 with mean sensitivity 0.72 and mean specificity 0.69, and the test showed low specificity in many settings. Because of this limited specificity, FibroTest™ can generate false positives—particularly in low-prevalence primary care populations—potentially prompting unnecessary invasive or costly follow-up testing.

    Non-invasive tests (serum biomarkers and transient elastography) are less well validated for some conditions: guideline statements note that NITs are better at ruling out advanced fibrosis than confirming it, and that non-invasive methods are not validated for diagnosis of NASH. The limitations of NITs versus biopsy should be recognized when applying results outside the better-studied contexts such as viral hepatitis.

    The following section provides the evidence base and guideline citations referenced in this policy (refs 23–52). These references support the statements on diagnostic accuracy, guideline recommendations, and the limitations of non-invasive tests described elsewhere in this document.

    For individuals with liver disease that do not meet the specified indications in this policy (MASLD/MASH, alcoholic hepatitis, or evaluation for cACLD with elevated liver stiffness), the use of ELF™, FibroTest®, HBV FibroSURE®, or HCV FibroSURE® does not meet criteria and is considered not medically necessary.

    No single biomarker or multimarker score reliably achieved a predefined acceptability threshold of AUC ≥0.80 to replace liver biopsy for detection of both NASH and clinically significant fibrosis in NAFLD cohorts. While some tests reached acceptable accuracy for selected endpoints (for example, SomaSignal for advanced fibrosis), overall evidence does not support substituting biomarkers alone for histological assessment when both NASH and significant fibrosis must be detected.

    Non-invasive tests have accuracy limits: guidelines emphasize that NITs are generally more reliable for excluding advanced fibrosis than confirming it, and that identification of advanced fibrosis or cirrhosis by biomarkers and/or elastography may require confirmation by liver biopsy depending on clinical context. Clinicians should interpret NIT results within guideline-recommended pathways and consider histological confirmation for diagnostic uncertainty or to guide management when necessary.

    This part of the document contains only references and publication history; it does not itself make independent 'not medically necessary' determinations beyond those stated in the policy body.

    Coding and Test Frequency

    ELF/FibroTest testing interval — once every six months
    Allowed frequencyELF™ (ELFTM) or FibroTest® testing permitted once every six months for indicated conditions
    Indications for intervalApplicable for individuals with MASLD (including MASH), alcoholic hepatitis, or to rule out cACLD with elevated liver stiffness
    Documentation requirementSupportive documentation of diagnosis or elevated liver stiffness is required when testing at this interval
    APRI threshold for significant fibrosis and cirrhosis
    Significant fibrosis (≥F2)APRI >0.5 suggests presence of significant fibrosis (≥F2)
    Cirrhosis (F4) — WHO contextAPRI >1.0 (or APRI >2.0 in WHO resource-limited guidance for cirrhosis) may indicate cirrhosis depending on clinical context

    Provider Actions, Documentation, and Billing Guidance

    Prior Authorization

    Authorization and frequency for ELF™/FibroTest®

    Services must meet authorization and medical necessity guidelines; for individuals with MASLD (including MASH), alcoholic hepatitis, or to rule out cACLD in those with elevated liver stiffness, ELF™ (ELFTM) or FibroTest® testing is permitted once every six months.

    Prior Authorization

    Use sequential or combined NITs for NAFLD staging

    When staging NAFLD, use of multiple noninvasive tests or sequential testing is recommended (for example, calculate FIB-4 first and, if >1.3 or indeterminate, follow with elastography or a second serum biomarker such as ELF™ or FibroTest®). Documentation of results may be required to justify further imaging or biopsy.

    Background and Scope

    Chronic liver disease (CLD) includes chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatic fibrosis reflects extracellular matrix deposition and remodeling and is a central process across these conditions. Serum biomarkers—both direct and indirect—and composite panels are used to estimate fibrosis stage noninvasively, but liver biopsy remains the reference standard with recognized sampling variability and procedural risks. Non-invasive tests can aid risk stratification and monitoring but have known limitations in specificity and in diagnosing NASH; guideline-directed use and confirmatory testing are advised where appropriate.

    Key Test and Term Definitions

    ELF — European Liver Fibrosis panel definition/reference
    DefinitionELF™ (Enhanced/European Liver Fibrosis panel) is a serum biomarker panel used to assess hepatic fibrosis
    Intended useReferenced as a serum-based fibrosis test used in NAFLD and other chronic liver diseases for staging and prognostication
    Performance noteELF has been reported with AUCs around 0.82–0.90 in some NAFLD studies
    FibroTest/FibroSure — panel components and purpose
    Panel componentsFibroTest/FibroSure incorporates alpha-2-macroglobulin, haptoglobin (alpha-2-globulin), gamma globulin, apolipoprotein A1, GGT, total bilirubin, plus age and sex
    PurposeUsed to estimate degree of hepatic fibrosis as a multibiomarker panel
    Policy Summary
    PayerOscar Health
    PolicySerum Testing for Hepatic Fibrosis in the Evaluation and Monitoring of Chronic Liver Disease
    Policy CodePolicy N/A
    Change TypeMinor editorial — no material coverage changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionProviders must document medical necessity and may order ELF™ or FibroTest® once every six months for MASLD/MASH, alcoholic hepatitis, or to evaluate elevated liver stiffness for cACLD.
    SourceLink
    On This Page
    Coverage Criteria for Serum and Multianalyte Fibrosis TestingCoding and Test FrequencyProvider Actions, Documentation, and Billing GuidanceBackground and ScopeKey Test and Term Definitions
    FIB-4 <1.3 negative predictive value

    Serial monitoring with NITs may inform management; combine serum and imaging-based NITs for improved accuracy

    WHO recommendations: In resource-limited settings prefer APRI for cirrhosis assessment (APRI >2 in adults). WHO (2024) recommends APRI >0.5 or transient elastography (TE) >7.0 kPa for significant fibrosis (≥F2) and APRI >1.0 or TE >12.5 kPa for cirrhosis (F4); TE or FibroTest may be preferred where available.APRI >0.5; APRI >1.0; APRI >2; TE >7.0 kPa; TE >12.5 kPa

    Clinical features of decompensated cirrhosis described in guideline

    NICE for NAFLD: ELF may be considered in patients with NAFLD to test for advanced fibrosis; offer ELF at recommended monitoring intervals (example: every 3 years in adults per guideline statements).ELF testing interval

    NICE recommendation for monitoring frequency.

    Primary care implementation: Ensure routine labs (ALT, AST, platelet count) are available to calculate simple NITs (e.g., FIB-4); automatic calculation and reporting of FIB-4 in at-risk primary care populations is recommended to improve risk stratification and linkage to care.population at risk: metabolic risk factors and/or harmful alcohol use

    EASL strong recommendation for primary care implementation.

    Use contextAPRI is recommended by WHO as preferred NIT in resource-limited settings to assess for cirrhosis
    Transient elastography thresholds
    Significant fibrosis (≥F2)>7.0 kPa by transient elastography (TE) suggests significant fibrosis (≥F2)
    Cirrhosis (F4)>12.5 kPa by transient elastography (FibroScan®) suggests cirrhosis (F4)
    Preferred useTE may be preferred where available and cost is not a major constraint (per WHO)
    APRI significant fibrosis/cirrhosis thresholds (alternate values noted)
    Significant fibrosis cutoffAPRI >0.5 suggests ≥F2 (significant fibrosis)
    Cirrhosis cutoff — common referencesAPRI >1.0 is referenced for cirrhosis; WHO also cites APRI >2.0 for cirrhosis in resource-limited settings
    Contextual interpretationAPRI thresholds should be applied with clinical judgment and in accordance with guideline context
    Liver stiffness measurement (LSM) for cACLD thresholds
    Suggestive threshold for cACLDLiver stiffness measurement (LSM) ≥10 kPa is suggestive of compensated advanced chronic liver disease (cACLD)
    Highly suggestive thresholdLSM ≥15 kPa is highly suggestive of cACLD
    Terminology notecACLD reflects the continuum of severe fibrosis and compensated cirrhosis where discrimination can be difficult
    Billing Rule

    Submit specific procedure codes for proprietary biomarker panels

    Specific proprietary and panel biomarker tests are listed with procedure codes; when requesting coverage or submitting claims, include the specific procedure code for proprietary tests (e.g., 0166U for LiverFASt™) as indicated in the coding section.

    Note

    No separate prior authorization rule specified

    This section of the policy does not establish additional prior authorization requirements beyond the need for services to meet authorization and medical necessity guidelines; no separate prior authorization rule is specified here.

    Note
    Step Therapy

    Stepwise testing: start with FIB-4, escalate as indicated

    Follow a stepwise testing approach in clinical pathways: begin with a simple, inexpensive test (e.g., FIB-4) and proceed to more specific testing (ELF™, FibroScan, or FibroTest®) for indeterminate or high-risk results.

    Note

    Preferred first-line testing: simple biomarkers or elastography

    Use simple serum biomarkers (APRI, FIB-4, NFS) or elastography as first-line noninvasive tests; combine biomarker panels with elastography as needed to improve diagnostic accuracy before using proprietary multianalyte assays.

    Step Therapy

    No step therapy rules provided

    No step therapy rules for laboratory or imaging tests are provided in the references section of this policy.

    Documentation Required

    Document indication and timing to support medical necessity

    Providers must submit accurate documentation supporting medical necessity and authorization per member benefits and applicable state rules; documentation should support the indication (e.g., MASLD/MASH, alcoholic hepatitis, or elevated liver stiffness for cACLD) and timing (tests like ELF™ or FibroTest® allowed once every six months for indicated conditions).

    Documentation Required

    Monitor and document routine labs every six months for cirrhosis

    For patients with cirrhosis, clinicians should monitor and document a basic metabolic panel, liver function tests, complete blood count, and PT/INR every six months to allow recalculation of Child-Pugh and MELD scores.

    Documentation Required

    Obtain ALT, AST and platelet count to calculate FIB-4/APRI

    Ensure routine investigations include ALT, AST and platelet count so simple noninvasive scores (e.g., FIB-4) can be calculated and reported, particularly in primary care for patients at risk of liver fibrosis.

    Documentation Required

    Cite guideline and evidence references (refs 23–52)

    Support clinical decisions and documentation with the cited evidence-based literature and guidelines listed in the references (refs 23–52).

    Denial Risk

    Adhere to coding/billing and indication rules to avoid denial

    Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed; use of ELF™, FibroTest®, HBV FibroSURE®, HCV FibroSURE® or multianalyte algorithmic assays (e.g., LIVERFASt™) outside their specified indications may not meet criteria and could be disallowed.

    Denial Risk

    False-positive risk with FibroTest™ may trigger unnecessary follow-up

    Because FibroTest™ has low specificity in NAFLD, its use in low-prevalence primary care settings can generate false positives that lead to unnecessary invasive and expensive follow-up testing—such downstream testing may be denied if not clinically indicated.

    • FibroTest mean AUC in NAFLD meta-analysis was 0.77 with mean specificity ~0.69.
    • Low specificity can produce false positives and increased downstream testing.
    Denial Risk

    Government coverage rules supersede policy and may cause denial

    If this policy conflicts with an applicable government policy (e.g., Medicare LCDs/NCDs or state Medicaid), the government policy will govern the determination and may result in denial if the government policy excludes coverage.

    Note

    References/publication history only — no added authorization rules

    This portion of the document contains references and publication history only and does not provide additional authorization or denial criteria.

    LimitationsFibroTest may have low specificity in some settings and should not be used alone for definitive diagnosis
    LIVERFASt™ — multianalyte assay with algorithmic analysis (explicitly not meeting criteria)
    Test typeLIVERFASt™ is a multianalyte assay that measures multiple biomarkers with algorithmic analysis to generate fibrosis, activity and steatosis staging
    Policy stanceUse of LIVERFASt™ and other multianalyte algorithmic assays DOES NOT MEET CRITERIA in this policy
    Reason for exclusionThese algorithmic multianalyte assays are explicitly excluded from permitted uses per policy guidance
    ELF — Enhanced Liver Fibrosis panel performance note (AUC range reported)
    Performance rangeELF reported AUC range approximately 0.82–0.90 in NAFLD diagnostic studies
    Clinical implicationELF may be used as a prognostic biomarker or when elastography is unavailable, per guideline summaries
    Evidence sourceDiagnostic accuracy data summarized in policy's evidence review
    FIB-4 — Fibrosis-4 index definition and cutoff usage
    DefinitionFIB-4 (Fibrosis-4 index) is a nonproprietary serum-based test used for initial fibrosis risk stratification
    Cutoff usageLow cutoffs (e.g., <1.3 or ~1.45) have good negative predictive value to exclude advanced fibrosis; elevated cutoffs prompt further testing
    Role in testing pathwayRecommended as a first-line/simple serum biomarker to identify patients who need further evaluation with TE or proprietary panels
    cACLD — compensated advanced chronic liver disease definition
    DefinitioncACLD (compensated advanced chronic liver disease) is a term proposed to encompass severe fibrosis and compensated cirrhosis as a continuum
    Clinical relevanceTerm used to reflect risk of developing portal hypertension and clinical decompensation even when asymptomatic
    LSM thresholdsLSM ≥10 kPa suggestive and ≥15 kPa highly suggestive of cACLD (BAVENO VI consensus referenced)
    APRI — AST-to-platelet ratio index definition and thresholds
    DefinitionAPRI (AST-to-platelet ratio index) is a simple non-invasive biomarker index calculated from AST and platelet count to assess fibrosis
    Common thresholdsAPRI >0.5 suggests significant fibrosis (≥F2); APRI >1.0 or APRI >2.0 referenced for cirrhosis depending on guideline/context
    WHO recommendationWHO recommends APRI as preferred NIT in resource-limited settings for assessing cirrhosis (APRI >2 in adults)
    Clinical practice guidelines — list of guideline sources cited (AASLD, EASL, AGA, WHO, CDC, NICE)
    Guideline sourcesAASLD (including AASLD-IDSA HCV guidance), EASL (and joint EASL-EASD-EASO statements)
    Public health organizationsWHO and CDC guidance cited (including WHO NIT thresholds update and CDC hepatitis screening guidance)
    Other bodiesNICE recommendations on NAFLD assessment and USPSTF HCV screening referenced in evidence list